{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:17:01Z","timestamp":1791818221363,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Concordia Pharmaceuticals"},{"name":"NIH\/NCI Cancer Center Support","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clml.2015.02.018","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T19:43:48Z","timestamp":1424375028000},"page":"433-438.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies"],"prefix":"10.1016","volume":"15","author":[{"given":"Talha","family":"Badar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.018_bib1","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.018_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.02.018_bib3","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2002.09.116","article-title":"Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"20","author":"Crul","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.018_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00690419","article-title":"The Ras signal transduction pathway","volume":"13","author":"Khosravi-Far","year":"1994","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.clml.2015.02.018_bib5","first-page":"25","article-title":"Interactions between p21ras proteins and their GTPase activating proteins","volume":"12","author":"Polakis","year":"1992","journal-title":"Cancer Surv"},{"key":"10.1016\/j.clml.2015.02.018_bib6","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1158\/1078-0432.CCR-04-2232","article-title":"Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts","volume":"11","author":"Illmer","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.018_bib7","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.018_bib8","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2005-08-3522","article-title":"Implications of NRAS mutations in AML: a study of 2502 patients","volume":"107","author":"Bacher","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.018_bib9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","article-title":"RAS and leukemia: from basic mechanisms to gene-directed therapy","volume":"17","author":"Beaupre","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.018_bib10","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/MCB.14.6.4193","article-title":"Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton","volume":"14","author":"Prendergast","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2015.02.018_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V82.2.590.590","article-title":"N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome","volume":"82","author":"Paquette","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.018_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.leu.2401044","article-title":"RAS, FMS and p53 mutations and poor\u00a0clinical outcome in myelodysplasias: a 10-year follow-up","volume":"12","author":"Padua","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.018_bib13","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.018_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0955-0674(99)00071-X","article-title":"The Ras branch of small GTPases: Ras family members don't fall far from the tree","volume":"12","author":"Reuther","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.clml.2015.02.018_bib15","first-page":"F51","article-title":"Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?","volume":"1333","author":"Cox","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2015.02.018_bib16","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1158\/1078-0432.CCR-04-1659","article-title":"Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors","volume":"11","author":"Papadimitrakopoulou","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.018_bib17","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/1078-0432.CCR-03-0412","article-title":"Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors","volume":"10","author":"Khuri","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.018_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-012-2071-z","article-title":"A\u00a0phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)","volume":"134","author":"Li","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.02.018_bib19","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3816\/CLM.2003.s.006","article-title":"Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"4","author":"Cortes","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clml.2015.02.018_bib20","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1074\/jbc.272.15.10232","article-title":"Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in\u00a0vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I","volume":"272","author":"Zhang","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.02.018_bib21","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.02.018_bib22","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1126\/science.8316833","article-title":"Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor","volume":"260","author":"Kohl","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.018_bib23","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1126\/science.8316834","article-title":"Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells","volume":"260","author":"James","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.018_bib24","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","article-title":"Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid","volume":"270","author":"Marom","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.02.018_bib25","doi-asserted-by":"crossref","first-page":"14019","DOI":"10.1073\/pnas.96.24.14019","article-title":"Novel Ras antagonist blocks human melanoma growth","volume":"96","author":"Jansen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.018_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid","volume":"1452","author":"Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clml.2015.02.018_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ardp.201300325","article-title":"Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment","volume":"347","author":"Ling","year":"2014","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.clml.2015.02.018_bib28","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1038\/cddis.2012.200","article-title":"Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms","volume":"4","author":"Charette","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2015.02.018_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","article-title":"Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors","volume":"65","author":"Tsimberidou","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2015.02.018_bib30","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","article-title":"Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer","volume":"30","author":"Laheru","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2015.02.018_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/JTO.0b013e318223c099","article-title":"A\u00a0phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations","volume":"6","author":"Riely","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clml.2015.02.018_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.018_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1078-0432.CCR-07-1532","article-title":"Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome","volume":"14","author":"Kurzrock","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.02.018_bib34","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A\u00a0phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.018_bib35","article-title":"Phase I\/II trial of the MEK1\/2 inhibitor trametinib (GSK1120212) in relapsed\/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease","volume":"120","author":"Borthakur","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2015.02.018_bib36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejca.2013.09.014","article-title":"Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients","volume":"50","author":"Goldinger","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2015.02.018_bib37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T04:43:59Z","timestamp":1598762639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S2152265015000476"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}